The financial terms of the deal were not disclosed.
Integrating Insightful Science’s software applications into Dotmatics cloud-first enterprise data management service will enable an end-to-end scientific research platform, the companies said. The goal is to facilitate more rapid data access, analysis and exchange between scientists around the world.
“Together our complementary businesses create an end-to-end cloud-first scientific research platform that stands apart in our collective ability to support data-driven research. We are beyond enthusiastic about the impact we can have on increasing the speed of scientific innovation, and ultimately helping to make the world a healthier, cleaner, and better place to live,” Insightful Science CEO Thomas Swalla said in a news release.
Dotmatics CEO Steve Gallagher said the No. 1 challenge for pharmaceutical, biotech and chemical innovation companies involves how to manage the enormous volume of lab-generated data. “This combination allows us to expand investments in our Dotmatics platform and strengthen our brand as a leading enterprise informatics solution provider. We will bring Insightful Science’s leading biologics applications to our customers, further accelerating their discovery processes. In addition, we have the opportunity to bring the Dotmatics cloud and collaboration capabilities to the diverse community of over 1 million scientists already using Insightful Science tools.”
Filed Under: Drug Discovery and Development, RD